ClinicalTrials.gg
Not yet recruitingNCT06878313Updated Mar 14, 2025

Role of Elastic Power in Acute Respiratory Distress Syndrome

An observational study in ARDS (Moderate or Severe) and Adult Patients, sponsored by Hospital El Cruce. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Hospital El Cruce · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Mechanical ventilation is essential for managing acute respiratory distress syndrome (ARDS), but it can also cause ventilator-induced lung injury (VILI) due to mechanical forces. VILI results from the interaction between lung structure and mechanical ventilation factors, such as tidal volume, plateau pressure, driving pressure, inspiratory flow, respiratory rate, and PEEP. Intrinsic factors like lung heterogeneity further increase the risk.

Elastic power (EP), a key component, is linked to repetitive alveolar stretching and disease progression.

Study Objectives:

Examine the correlation between elastic power and pulmonary hyperinflation. Compare EP's sensitivity and specificity with other overdistension markers like driving pressure, plateau pressure, upper inflection point, and compliance.

Read the detailed description

Introduction:

Mechanical ventilation is a fundamental intervention in the management of acute respiratory distress syndrome (ARDS), providing life support while the lungs recover. However, it can also induce ventilator-induced lung injury (VILI) due to the mechanical forces applied during ventilation.

VILI arises from the interaction between lung structure-mainly composed of elastin and collagen fibers embedded in a hydrated extracellular matrix-and the mechanical factors imposed by ventilation. Among these, tidal volume (Vt), plateau pressure (PPlat), driving pressure (∆P), inspiratory flow (Ṹ), respiratory rate (RR), and, in certain cases, positive end-expiratory pressure (PEEP) have been identified as key determinants of lung injury. Additionally, intrinsic factors such as lung heterogeneity and reduced ventilatory capacity may increase the risk of VILI even under protective ventilation strategies.

The positive pressure generated by mechanical ventilation is distributed between the lungs and the thoracic cage. The pressure applied directly to the lungs is known as transpulmonary pressure (Ptp), defined as the difference between alveolar pressure and pleural or esophageal pressure. Ptp expands the alveoli until it balances the tension of the alveolar wall, which opposes this expansion. Alveolar wall tension directly depends on the surface tension of the liquid lining the alveoli. Under normal conditions, pulmonary surfactant reduces alveolar surface tension. However, in ARDS, inflammation and alveolar damage degrade and inhibit surfactant production, increasing surface tension, promoting alveolar collapse and stiffness.

Although the terms "pressure" and "tension" may seem synonymous, the relationship between intra-alveolar pressure and alveolar wall tension is non-linear, as described by Laplace's law:

Tension= Pressure × Radius / 2 × Thickness

This implies that, under the same Ptp, ventral alveoli (larger and with thinner walls) experience greater deformation and tension than dorsal alveoli (smaller and with thicker walls). In this context, if alveolar deformation exceeds the structural tolerance threshold, it can lead to microfractures, pulmonary edema, hemorrhage, and inflammatory activation, contributing to multiple organ dysfunction and increased mortality.

Although alveolar tension cannot be directly measured in clinical settings, tools such as computed and electrical impedance tomography allow for indirect estimation of alveolar overdistension risk. Without airflow, alveolar tension varies between a baseline value-determined by PEEP-and a maximum value at end-inspiration-defined by PPlat. Thus, lung stress can be expressed as:

Stress (ΔPtp)= Ptp at end-inspiration-Ptp at end-expiration\text

However, lung stress and strain are static variables that do not fully capture the dynamic changes occurring during the ventilatory cycle. Animal studies have shown that VILI correlates with flow magnitude, suggesting that higher deformation rates reduce the alveolus's ability to adapt. This phenomenon is described by the Kelvin-Voigt equation for viscoelastic materials:

Stress= k × Strain + η × Strain Rate

where k represents the Young's modulus of elasticity and η the viscosity modulus.

Since VILI results from a combination of pressure, volume, and flow, mechanical power emerges as an integrative concept that expresses these variables in terms of energy per unit of time. It is estimated that a mechanical power exceeding 12 J/min surpasses the lung's adaptive capacity, increasing the risk of VILI and mortality in ARDS. Among its components, elastic power (EP) is responsible for repetitive alveolar stretching and appears to be most directly associated with ARDS severity.

Study Objectives:

  1. To evaluate whether elastic power correlates with pulmonary hyperinflation.
  2. To compare the sensitivity and specificity of elastic power with other overdistension markers, such as driving pressure (∆P), plateau pressure (PPlat), the upper inflection point of the V/P curve, and respiratory system compliance (CRS).

Materials and Methods:

Ethical Considerations: The study requires evaluation and subsequent approval from the institution's ethics and research committee, following the principles established in the Declaration of Helsinki. The study was registered on ClinicalTrials.gov before patient inclusion. Inclusion in the study requires prior informed consent authorization from an adult family member.

Inclusion Criteria: Adult patients (≥18 years) with moderate to severe ARDS, according to the Berlin expert consensus definition, will be prospectively and consecutively included.

Exclusion Criteria: Patients will be excluded if they meet any of the following criteria:

History of emphysema, asthma, or pneumothorax. Severe instability at the time of the study that would prevent the recruitment maneuver, defined by at least one of the following indicators: SaO2 ≤ 90%, shock requiring more than 0.5 γ/kg/min of norepinephrine, complex arrhythmia, myocardial ischemia, or intracranial hypertension unresponsive to first-line measures.

Patients with do-not-resuscitate orders or pregnant women. Procedure: Under deep sedation and analgesia (Cambridge-Ramsay: V to VI) and using neuromuscular blocking agents, patients will be ventilated in the supine position using a ventilator (SERVO-s, Maquet, Germany) in volume control mode (VCV) with a tidal volume of 6 ml/kg of predicted body weight (PBW), a respiratory rate of 18 breaths per minute, and a constant flow.

After performing a gentle aspiration of airway secretions using a closed circuit, PEEP titration will begin stepwise, increasing in increments of 2 cmH2O starting from 8 cmH2O (baseline condition), progressively increasing until a maximum of 20 cmH2O or a plateau pressure of 45 cmH2O is reached, whichever occurs first.

At each PEEP level, respiratory mechanics, vital parameters, and impedance tomography images will be evaluated after a short stabilization period of the studied variables.

Finally, after determining the optimal PEEP based on the best respiratory system compliance (CRS), PEEP will be titrated 2 cmH2O above its optimal value to prevent alveolar derecruitment and improve patient safety.

Criteria for Stopping the Procedure: These include SaO2 below 85%, complex arrhythmias, or hemodynamic instability (mean arterial pressure \<60 mmHg).

Measurement of Transpulmonary Pressures: Since direct measurement of pleural pressure (Ppl) is complicated in clinical practice, esophageal pressure (Pes) was used as a surrogate. An inflatable balloon catheter will be inserted into the lower third of the esophagus while the patient remains in the supine position, according to standard technique. The balloon will be inflated with the minimum volume of air necessary to ensure accurate pressure recordings.

Transpulmonary pressure (Ptp) measurements will be obtained using a respiratory mechanics monitoring system (FluxMed GrT, Buenos Aires, Argentina).

Electrical Impedance Tomography (EIT): EIT is a medical imaging technology that detects impedance changes through specific image algorithms by applying low-intensity electrical currents and measuring surface voltages via electrodes placed around the chest.

In this study, continuous signal recording will be performed using the commercial device with 32 electrodes, Infivision ET1000 (Infivision Medical Imaging Technology Co., Ltd., Beijing, China). This device allows non-invasive assessment of both ventilation and perfusion in four lung regions of interest (ROIs), defined by horizontal lines within the thoracic contour: ROI 1 (ventral), ROI 2 (central ventral), ROI 3 (central dorsal), and ROI 4 (dorsal).

Perfusion signals will be extracted using frequency domain filtering techniques. By analyzing the signal spectrum, the cardiac signal (which occurs at higher frequencies than the respiratory signal) will be isolated using a digital bandpass filter. Areas identified as hyperinflated will be quantified as a percentage relative to the respective ROI.

Evaluation of Elastic Power:

Elastic Power (EP): EP = 0.098 × RR × [(Vt × PEEP) + (Vt × ΔP) / 2].

02

Conditions studied

  • ARDS (Moderate or Severe)
  • Adult Patients

Keywords

  • ARDS
  • VILI
  • Mechanical Ventilation
03

In context

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's planned enrollment of 20 is below the median of 150 across 195 observational studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Hospital El Cruce is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients (≥18 years) with moderate-to-severe acute respiratory distress syndrome (ARDS) included in UCI.

Eligibility criteria

Inclusion Criteria: Adult patients (≥18 years) with moderate-to-severe acute respiratory distress syndrome (ARDS), as defined by the Berlin criteria, were prospectively and consecutively included.

-

Exclusion Criteria: Patients were excluded if they met at least one of the following criteria:

  • History of emphysema, asthma, or pneumothorax.
  • Severe instability at the time of the study preventing the PEEP titration maneuver, defined by at least one of the following indicators: SaO₂ ≤ 90%, shock requiring >0.5 γ/kg/min of norepinephrine, complex arrhythmia, myocardial ischemia, or intracranial hypertension to initial treatment.
  • Patients with do-not-resuscitate orders and pregnant women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Comparison between pulmonary hyperinflation and pulmonary elastic power

    Time frame: 1 hour

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Xie Y, Shi J, Liu S, Chen X, Wang Y, Li X, Yan Y. Association of elastic power in mechanical ventilation with the severity of acute respiratory distress syndrome: a retrospective study. Eur J Med Res. 2024 Jan 3;29(1):5. doi: 10.1186/s40001-023-01577-7. PubMed 38173033 ↗
  • Modesto I Alapont V, Aguar Carrascosa M, Medina Villanueva A. Stress, strain and mechanical power: Is material science the answer to prevent ventilator induced lung injury? Med Intensiva (Engl Ed). 2019 Apr;43(3):165-175. doi: 10.1016/j.medin.2018.06.008. Epub 2018 Nov 5. No abstract available. English, Spanish. PubMed 30409677 ↗
  • Marini JJ, Thornton LT, Rocco PRM, Crooke PS. From pressure to tension: a model of damaging inflation stress. Crit Care. 2023 Nov 15;27(1):441. doi: 10.1186/s13054-023-04675-4. PubMed 37968744 ↗
  • Gattinoni L, Marini JJ, Collino F, Maiolo G, Rapetti F, Tonetti T, Vasques F, Quintel M. The future of mechanical ventilation: lessons from the present and the past. Crit Care. 2017 Jul 12;21(1):183. doi: 10.1186/s13054-017-1750-x. PubMed 28701178 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.

Of 55 non-industry observational studies under Lymphoma, Follicular, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 165. This study's planned 12 months is below that.

Counting every sponsor, half of 81 studies reached it within 49 months; a quarter within 34 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 14, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Apr 1, 2026
CompletionEst.
Jul 1, 2026
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06878313
Lead sponsor
Hospital El Cruce
Responsible party
Nestor Pistillo (Head of intensive care, Hospital El Cruce) — Principal investigator
First posted
Mar 14, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Mar 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion